東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Monoclonal antibodies in headache = ...

Maassen van den Brink, Antoinette.

FindBook

Google Book

Amazon

博客來

Monoclonal antibodies in headache = from bench to patient /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Monoclonal antibodies in headache/ edited by Antoinette Maassen van den Brink, Paolo Martelletti.
其他題名:	from bench to patient /
其他作者:	Maassen van den Brink, Antoinette.
出版者:	Cham :Springer International Publishing : : 2021.,
面頁冊數:	x, 172 p. :ill., digital ;24 cm.
內容註:	The CGRP family of neuropeptides and their receptors in the trigeminovascular system -- Pharmacology; where do the mAbs act, gepants vs mAbs -- Monoclonal Antibody Biology -- Guidelines for clinical trials -- Human Models -- CGRP Antibodies for Animal Models of Primary and Secondary Headache Disorders -- Galcanezumab -- Eptinezumab -- Erenumab -- Fremanezumab -- Potential side effects and pregnancy -- Real-world data, clinical practice so far -- Migraine vs Cluster headache and potential other indications.
Contained By:	Springer Nature eBook
標題:	Headache - Treatment. -
電子資源:	https://doi.org/10.1007/978-3-030-69032-8
ISBN:	9783030690328

Monoclonal antibodies in headache = from bench to patient /
Monoclonal antibodies in headachefrom bench to patient /[electronic resource] :edited by Antoinette Maassen van den Brink, Paolo Martelletti. - Cham :Springer International Publishing :2021. - x, 172 p. :ill., digital ;24 cm. - Headache,2197-652X. - Headache..

The CGRP family of neuropeptides and their receptors in the trigeminovascular system -- Pharmacology; where do the mAbs act, gepants vs mAbs -- Monoclonal Antibody Biology -- Guidelines for clinical trials -- Human Models -- CGRP Antibodies for Animal Models of Primary and Secondary Headache Disorders -- Galcanezumab -- Eptinezumab -- Erenumab -- Fremanezumab -- Potential side effects and pregnancy -- Real-world data, clinical practice so far -- Migraine vs Cluster headache and potential other indications.

Intended to promote a more appropriate and modern therapeutic approach to migraine management, this book is the first to deal with monoclonal antibodies in this context. Authored by the most respected migraine experts from around the globe and drawing on the lessons learned in both clinical trials and clinical practice, it reviews the current state of knowledge on this important therapeutic innovation, which has produced impressive data in randomized controlled trials, and the efficacy and safety of which have been confirmed in day-to-day real-world use. Given its scope, the book will appeal to a broad range of specialists, including pharmacologists, clinical pharmacologists, neurologists and internists, but also to residents and medical students.

ISBN: 9783030690328

Standard No.: 10.1007/978-3-030-69032-8doiSubjects--Topical Terms:

1961583
Headache
--Treatment.

LC Class. No.: RC392 / .M65 2021

Dewey Class. No.: 616.849106

National Library of Medicine Call No.: WL 342

Monoclonal antibodies in headache = from bench to patient /
LDR:02337nmm a2200349 a 4500 001 2240145
003 DE-He213
005 20210428212815.0
006 m d
007 cr nn 008maaau
008 211111s2021 gw s 0 eng d
020 $a 9783030690328 $q (electronic bk.)
020 $a 9783030690311 $q (paper)
024 7 $a 10.1007/978-3-030-69032-8 $2 doi
035 $a 978-3-030-69032-8
040 $a GP $c GP
041 0 $a eng
050 4 $a RC392 $b .M65 2021
060 4 $a WL 342
072 7 $a MJ $2 bicssc
072 7 $a MED045000 $2 bisacsh
072 7 $a MJ $2 thema
082 0 4 $a 616.849106 $2 23
090 $a RC392 $b .M751 2021
245 0 0 $a Monoclonal antibodies in headache $h [electronic resource] : $b from bench to patient / $c edited by Antoinette Maassen van den Brink, Paolo Martelletti.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a x, 172 p. : $b ill., digital ; $c 24 cm.
490 1 $a Headache, $x 2197-652X
505 0 $a The CGRP family of neuropeptides and their receptors in the trigeminovascular system -- Pharmacology; where do the mAbs act, gepants vs mAbs -- Monoclonal Antibody Biology -- Guidelines for clinical trials -- Human Models -- CGRP Antibodies for Animal Models of Primary and Secondary Headache Disorders -- Galcanezumab -- Eptinezumab -- Erenumab -- Fremanezumab -- Potential side effects and pregnancy -- Real-world data, clinical practice so far -- Migraine vs Cluster headache and potential other indications.
520 $a Intended to promote a more appropriate and modern therapeutic approach to migraine management, this book is the first to deal with monoclonal antibodies in this context. Authored by the most respected migraine experts from around the globe and drawing on the lessons learned in both clinical trials and clinical practice, it reviews the current state of knowledge on this important therapeutic innovation, which has produced impressive data in randomized controlled trials, and the efficacy and safety of which have been confirmed in day-to-day real-world use. Given its scope, the book will appeal to a broad range of specialists, including pharmacologists, clinical pharmacologists, neurologists and internists, but also to residents and medical students.
650 0 $a Headache $x Treatment. $3 1961583
650 0 $a Monoclonal antibodies $x Therapeutic use. $3 656052
650 1 4 $a Internal Medicine. $3 858559
650 2 4 $a Neurology. $3 588698
650 2 4 $a Psychopharmacology. $3 568143
700 1 $a Maassen van den Brink, Antoinette. $3 3385682
700 1 $a Martelletti, Paolo. $3 3217819
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
830 0 $a Headache. $3 2132792
856 4 0 $u https://doi.org/10.1007/978-3-030-69032-8
950 $a Medicine (SpringerNature-11650)